menu search

Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral ...

November 4, 2023, 12:00 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)

– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...

November 3, 2023, 12:30 pm

Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...

November 3, 2023, 10:00 am

Poolbeg's lead asset to be in the spotlight at leading medical conference

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste...

November 3, 2023, 3:32 am

Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...

October 31, 2023, 9:15 am

Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev...

October 31, 2023, 9:05 am

Scancell makes strong progress with lead immunotherapy assets

Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s financial year ending April 30 included a positive data reading arising...

October 31, 2023, 4:48 am

Why is medicenna therapeutics (mdna) stock down today?

Medicenna Therapeutics (NASDAQ: MDNA ) stock is falling on Monday after the immunotherapy company aler...

October 30, 2023, 9:29 am

Carisma to present first results from in vivo car-m collaboration with moderna at sitc 2023

-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data ...

October 25, 2023, 9:11 am

Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...

October 25, 2023, 9:05 am

Harpoon therapeutics stock soars on ‘promising' lung cancer drug results

Harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinical-stage ...

October 23, 2023, 9:32 am

Merck's keytruda gets u.s. fda's nod for expanded use in lung cancer

The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunoth...

October 16, 2023, 6:58 pm

Immix biopharma completes 3rd nxc-201 engineering batch at its u.s. car-t manufacturing site

Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. NXC-201 is manufactured at o...

October 16, 2023, 1:05 pm

Gsk cancer immunotherapy receives backing from key ema committee

GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immunotherapy drug, Jemperli (dostarlimab), has been recom...

October 16, 2023, 4:02 am

Alpine immune sciences to present initial clinical data on povetacicept in autoimmune glomerulonephritis in a late breaker poster session at american society of nephrology kidney week 2023

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy<...

October 13, 2023, 9:05 am

Merck immunotherapy shows further promise in lung cancer

Merck & Co confirmed that its cancer drug Keytruda has successfully met the second of its two primary targets in a phase III clinical trial,  showi...

October 10, 2023, 9:11 am

Harpoon therapeutics to present interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage ...

October 9, 2023, 4:17 pm

Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immun...

October 9, 2023, 12:10 pm


Search within

Pages Search Results: